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RÉSUMÉ 
 
Objectif: Évaluer les défis de la mobilité chez les personnes âgées atteintes de 
dégénérescence maculaire reliée à l’âge (DMLA), de glaucome ou de dystrophie 
cornéenne de Fuchs et les comparer avec les personnes âgées n’ayant pas de maladie 
oculaire.   
Devis: Étude transversale de population hospitalière  
Participants: 253 participants (61 avec la DMLA, 45 avec la dystrophie cornéenne 
de Fuchs, 79 avec le glaucome et 68 contrôles) 
Méthodes: Nous avons recruté les patients parmi ceux qui se font soigner dans les 
cliniques d’ophtalmologie de l’Hôpital Maisonneuve-Rosemont (Montréal, Canada) 
de septembre 2009 à octobre 2010.  Les patients atteints de la DMLA ou de la 
maladie de Fuchs ont une acuité visuelle inférieure à 20/40 dans les deux yeux, tandis 
que les patients avec du glaucome ont un champ visuel dans le pire œil inférieur ou 
égal à -4dB.  Les patients contrôles, qui ont été recrutés à partir des mêmes cliniques, 
ont une acuité visuelle et un champ visuel normaux.  Nous avons colligé des données 
concernant la mobilité à partir des questionnaires (aire de mobilité et chutes) et des 
tests (test de l’équilibre monopodal, timed Up and Go (TUG) test).  Pour mesurer la 
fonction visuelle nous avons mesuré l’acuité visuelle, la sensibilité au contraste et le 
champ visuel.  Nous avons également révisé le dossier médical.  Pour les analyses 
statistiques nous avons utilisé les régressions linéaire et logistique.  
Critères de jugement principaux: aire de mobilité, équilibre, test timed Up and Go, 
chutes 
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Résultats: Les trois maladies oculaires ont été associées à des patrons différents de 
limitation de la mobilité.  Les patients atteints de glaucome ont eu le type le plus 
sévère de restriction de mobilité; ils ont une aire de mobilité plus réduite, des scores 
plus bas au test TUG et ils sont plus enclins à avoir un équilibre faible et à faire plus 
de chutes que les contrôles (p < 0.05).  De plus, comparativement aux contrôles, les 
patients ayant de la DMLA ou  la dystrophie cornéenne de Fuchs ont eu une aire de 
mobilité réduite (p < 0.05).  Les chutes n’ont pas été associées aux maladies oculaires 
dans cette étude.  
Conclusions: Nos résultats suggèrent que les maladies oculaires, et surtout le 
glaucome, limitent la mobilité chez les personnes âgées. De futures études sont 
nécessaires pour évaluer l’impact d’une mobilité restreinte chez cette population pour 
pouvoir envisager des interventions ciblées qui pourraient les aider à maintenir leur 
indépendance le plus longtemps possible. 
Mots-clés: aire de mobilité, maladie oculaire, mobilité  
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ABSTRACT 
 
Objective:  To examine the extent of mobility limitations in patients with age-related 
macular degeneration (AMD), glaucoma, or Fuchs corneal dystrophy as compared to 
a control group of older adults with good vision.   
Design:  Cross-sectional hospital-based study 
Participants: 253 people (61 with AMD, 45 with Fuchs, 79 with glaucoma, and 68 
controls) 
Methods: Patients were recruited from the ophthalmology clinic of Maisonneuve-
Rosemont Hospital (Montreal, Canada) from September 2009 until October 2010.  
Patients with AMD and Fuchs had to have visual acuity in the better eye of worse 
than 20/40 while patients with glaucoma had to have visual field deficit in their worse 
eye of at least -4dB.  Control patients who had normal visual acuity and visual field 
were recruited from the same clinic.  Questionnaire (life space and falls) and 
performance-based (one-legged balance test, timed Up and Go (TUG) test) mobility 
data were collected, visual acuity, contrast sensitivity, and visual field were assessed, 
and the medical record was reviewed.  Linear and logistic regression were used.   
Main Outcome Measures:  Life space, balance, timed Up and Go, falls 
Results:  The three eye diseases were associated with different patterns of mobility 
limitations.  Patients with glaucoma had the most types of mobility limitations as they 
had reduced life space, had worse TUG scores, and were more likely to have poor 
balance than the control group (p < 0.05).  Compared to controls, patients with AMD 
or Fuchs corneal dystrophy had reduced life space (p < 0.05).  Falls were not related 
to eye disease in this study.   
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Conclusions:  Our results suggest that eye diseases, especially glaucoma, restrain the 
mobility of older people.  It is important to further explore the impact of eye disease 
on mobility in this population in order to develop interventions that would help 
affected older adults maintain their independence. 
Key-words:  life space, eye disease, mobility 
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CHAPTER I   INTRODUCTION 
 
I.1. Mobility in Older Adults 
 
The loss of mobility is a serious concern in older adults. Mobility problems 
have been recognized as the most frequent cause of disability in older men and 
women1. Shumway-Cook et al., in a cross-sectional study of 12,769 adults from the 
2001 Medicare Current Beneficiary Community Survey of respondents aged 65 and 
over, found that half had self-reported mobility impairment2. In 2001, Statistics 
Canada assessed self-reported mobility impairment in adults age 18 and older. The 
study revealed that mobility-related disability prevalence was 31.5% for persons 
aged 65 and over3.  
Although there are many factors that can cause mobility loss, vision plays an 
important role in mobility. Poor function in visual acuity, contrast sensitivity, or 
visual field have been related to worse mobility outcomes such as falls4, poor 
balance5, and car crashes6. Yet, there are very little data on how specific eye diseases 
are related to mobility limitations. This knowledge is necessary so that when patients 
have been diagnosed with an eye disease, they know what mobility risks are 
associated with that disease. This knowledge will also help us to know how to better 
help patients with eye disease with interventions designed to enhance mobility.  
 
 
I.2. Specific Objectives and Significance 
 
The present research set out to evaluate the association of eye disease with 
mobility limitations in patients over 65 years old. The study focused on eye diseases 
that are associated with age such as age-related macular degeneration, glaucoma, and 
Fuchs corneal dystrophy. The mobility performance of subjects with the above-
mentioned eye diseases was compared to normally sighted subjects of similar age 
using standardized questionnaires and tests. 
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This thesis has 3 major objectives: 
1. To determine the relationship between eye disease and life space 
2. To determine the relationship between eye disease and performance-based  
measures such as one-legged balance and the timed Up and Go Test 
3. To determine the relationship between eye disease and falls 
 
 
 
There are many reasons why this research is important. First, given the fact 
that the Canadian population is getting older, the incidence and prevalence of age-
related eye disease will increase considerably. Second, older people who develop 
mobility disability may go on to develop more severe disability and become a burden 
on the healthcare system and on their families. Third, this research could be used by 
clinicians and workers in the social services network to assist patients with eye 
disease by looking for signs of mobility difficulties so they can orient their patients 
toward eye rehabilitation services and programs. Moreover, the more we understand 
about the relationship between eye disease and mobility loss, the better we may be 
able to intervene to prevent that loss.   
 
 
I.3. Organization of the Thesis 
 
This master’s thesis is composed of 5 chapters. The literature review 
presented in Chapter II is structured in 8 sections which describe the aging 
population of Canada, the consequences of mobility loss in older adults, whether 
mobility loss can be prevented, how mobility is typically measured, a description of 
the eye diseases of interest, and what we know about the eye diseases of interest and 
mobility loss. Chapter III will describe pilot data and sample size calculations. 
Chapter IV comprises an article which has been submitted for publication entitled: 
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“Eye Disease and Mobility Limitations in Older Adults”. Chapter V goes into greater 
detail on the findings and on the clinical implications of the findings. 
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CHAPTER II   LITERATURE REVIEW 
 
II.1. Aging in Canada 
 
Most industrialized societies, including Canada and Quebec, are now facing a 
demographic shift toward an older population. Currently, 4,687,400 out of 
33,739,900 people in Canada are aged 65 and over7. In Quebec, there are 1,075,467 
adults over age 65 years from a total population of 7,828,879.8  
According to demographic statistics, the percentage of people in Quebec aged 
65 and over was 7% in 1971 and 14.6% in 2008. The predictions for 2031 indicate 
that 25% of the population will be over 65 years old. The median age ascended from 
26 years in 1971 to 41 years in 2008, and is predicted to be 47 years in 2031.9 The 
aging of the population and the greater longevity of individuals will lead to 
increasing numbers of older people, and also, unfortunately, greater numbers of 
people who suffer from age-related disease.  
 
 
II.2. Consequences of Mobility Loss in Older Adults 
 
The dangers of mobility impairment are significant.  Mobility disability is 
often the first step on the path to disability10. Mobility disability can lead to loss of 
independence, increased risk of cardiovascular disease11, nursing home admission12, 
decreased social interaction, and can increase the risk of mortality11.  Therefore, it is 
crucial to understand the risk factors for mobility loss so that mobility loss can be 
prevented or delayed as long as possible.   
 
 
II.3. Prevention of Mobility Loss in Older Adults 
 
There is some evidence from randomized controlled clinical trails that 
mobility loss can be prevented in older adults.  This is significant because the results 
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of the present study could be used to design interventions tailored to patients with 
eye disease.   
 
 
II.3. 1.Exercise-based Interventions 
 
A systematic review by Howe et al in 2007 examined the efficacy of exercise 
interventions designed to improve mobility in older people living in the community 
or in institutional care. They included 35 randomized or quasi-randomized clinical 
trails, which included 2883 participants. They concluded that exercise interventions 
do lead to improvements in mobility in older adults. The exercise routines with the 
greatest impact were those targeting gait, balance, and coordination.  The authors 
warn that these results should be interpreted with caution due to the lack of 
homogeneity of the randomized clinical trials (RCTs) and the fact that some RCTs 
suffered from methodological limitations. 13  
Some randomized clinical trials have been done in long-term care facilities 
and have also shown exercise to benefit mobility, strength, flexibility and balance. 
Therefore, there is some evidence that exercise can improve mobility in community 
and long-term care settings.  However, none of these studies included people with 
substantial vision loss.   
 
 
II.3. 2.Interventions for those with Impaired Vision 
 
 Very little research has been done to evaluate interventions to improve 
mobility in people with low vision. Orientation and mobility (O&M) programs are 
often part of low vision rehabilitation. These programs are designed to teach skills to 
people with low vision so that they can confidently navigate in unfamiliar 
surroundings or when performing tasks. However, many of these programs have 
been based on clinical opinion and have not been rigorously tested in RCTs. A 
review conducted by Virgili and Rubin only found two small quasi-randomized trials 
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that examined O & M programs. Neither trial found any difference between adults 
who received the interventions and those who did not. The goal of these 
rehabilitation techniques was to teach the participants new orientation and mobility 
skills in order to be able to cope with reduced visual data. 14 
There is some RCT evidence, though, of the efficacy of low vision 
rehabilitation on mobility. For example, an RCT by Stelmack examined mobility as a 
secondary outcome.  This study included 126 veterans older than 70 with a primary 
eye diagnosis of maculopathy and a visual acuity less than 20/100 in the better seeing 
eye. The primary outcome measure was the change in visual reading ability. The 
outcomes were measured at baseline and after a 4-month follow-up period. The out-
patient rehabilitation program consisted of five weekly sessions at the low-vision 
clinic and one home visit. A low vision therapist and optometrist provided education 
and counselling, correction of refractive errors, eccentric viewing training, provision 
of low-vision assistive device, assigned homework, and home modifications. 
Mobility was assessed from answers to subsets of items in the VA LV VFQ-48 
(Veterans Affairs Low vision Visual Functioning Questionnaire) and Physical 
Functioning Scale of the Short-Form 36 (SF-36). When compared with the control 
group, patients in the treatment group reported improvement in mobility (difference 
logOR = 0.84; 95%Cl = 0.58-1.10; p < 0.01; effect size, 1.14). 15 
To summarize, there is some evidence that mobility loss we can be prevented 
or delayed, but more RCT evidence is needed in those with vision loss and for a 
greater diversity of mobility outcomes. 
 
 
II.4. Measurement of Mobility 
 
Generally speaking, mobility is defined as the ability to move purposely by 
walking, by using an assistive device, or by using transportation from one’s home, to 
the neighborhood, and to the areas outside the town.16 It is an indispensable element 
in maintaining independence in daily life and in preventing disability. 
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There are questionnaire-based and performance-based measures to assess 
mobility. The measures used in this project such as life-space, the timed Up and Go 
test, balance, and falls will be the primary focus. Other commonly used mobility 
measures will be then described. 
 
 
II.4.a. Life Space Assessment 
 
A global measure of mobility is life space.  In 1985, May et al.17 introduced 
the first specific spatial measure of life-space mobility. Thirty people aged 64 to 88 
who were living at home, completed a life-space diary for a month. The researchers 
defined life space as the zone through which a person moved over a specific period 
of time. A zone extended from one’s home to one’s town or geographic region. All 
the data written in the diaries were afterwards converted to a life-space diameter 
score that revealed the dimension of each subject’s mobility over a one-month 
period. These scores were significantly correlated with gait speed (r = 0.79, p < 0.01) 
and sway path measurements (r = -0.65, p < 0.01). The life space approach requires 
good cooperation from the participant to fill out and return the diary. 
In 1990, Tinetti and Ginter 18 introduced the Nursing Home Life-Space 
Diameter as an adaptation for nursing home settings and as a measure of the extent 
and frequency of mobility among 25 skilled nursing facility residents. The data were 
collected via a questionnaire that was administered to the head nurse in each nursing 
home facility. The score indicates the frequency of a resident’s movement within his 
or her room and outside the room, the unit, and the facility. A lower score was 
associated with decreased vision (p < 0.01), presence of neurological conditions (p < 
0.06), and a greater need for assistance with activities of daily living (p < 0.01). 
In 1999, Stalvey et al. developed a brief, self-report questionnaire (Life-Space 
Questionnaire LSQ) of nine items in order to evaluate participants’ life-space during 
the past three days preceding the interview. The study included 242 participants older 
than 55 years who were recruited from eye care clinics. The objective of the study 
was to validate the reliability of the LSQ. The nine consecutive questions ask about 
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concentrically larger areas 1) room in which the person sleeps, 2) area immediately 
outside the home, 3) area outside the home, 4) the neighbourhood, 5) area outside the 
neighbourhood, 6) town, 7) county, 8) state, or 9) outside the Unites States. 
Participants answered with “yes”, scored as 1 or “no”, scored as 0, to all 9 questions; 
final individual scores were ranging from 0 to 9, larger scores suggesting larger life 
space. The study concluded that, in evaluating mobility, the information provided by 
LSQ is not redundant in comparison with other physical measurements, since the 
unshared variance is about 70%. Life space was significantly associated with mental 
status, depressive symptoms, vision (useful field of view), driving, and mobility (p < 
0.05).19 The LSQ does not account for whether the participant needed assistance.  
Later, in 2003, Baker et al developed the Life Space Assessment, which goes 
beyond the LSQ because it takes assistance into account and because it was designed 
to assess life space over the last month. 20 This tool assesses the spatial extent of a 
person in a given time, the frequency of going to different life space levels, and 
whether the patient required assistance from a technical device or from a person. The 
habits of displacement were evaluated as concentric zones which expand from the 
place where the person sleeps to outside one’s town during the month before the 
interview (bedroom, area outside the home, neighbourhood, outside the 
neighbourhood, outside the town). They defined a composite measure of life-space 
(LS-C) as being a combination of life space level attained, degree of independence, 
and frequency of attainment. Scores were calculated for each level by multiplying the 
life-space level, the degree of independence, and the frequency of attainment (see 
Figures 1 and 2 for English and French versions). At the end, the level-specific 
values were summed giving a score ranging from 0-120. Data were collected among 
306 community-dwelling subjects aged 65 and older. The authors examined the test-
retest reliability of the LSA data at baseline, after two weeks and six months 
respectively via telephone interview. The authors ascertained that the LSA revealed a 
high grade of stability at baseline and after two weeks (interclass correlation 
coefficient = 0.96), but it was sensitive to change after a 6-month follow-up period. 
Moreover, life space was strongly correlated as expected with measures of physical 
and mental health such as physical performance, activities of daily living (ADL), 
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instrumental activities of daily living (IADL), depression, self-reported health, and 
the number of comorbidities indicating its validity (p < 0.05).  
The LSA was then used in a larger study. The University of Alabama at 
Birmingham study of Aging Life Space-Assessment (LSA)21 assessed the life-space 
over the month preceding the interview, taking into account not only the area, but 
also the frequency of movement and the assistance needed such as, special 
equipment or presence of another person. The 998 subjects were recruited among 
community-dwelling older adults (older than 65) and the follow-up period was 18 
months. This prospective observational population-based study was designed to 
analyze the existence of associations between LSA and physical function (ADL, 
IADL), physical performance (Short Physical Performance Battery [SPPB]), 
cognition, depression and, sociodemographic factors. Life-space was associated with 
mobility, physical performance tests, transportation difficulty, mental status, and 
depression (p < 0.05). 
The LSA questionnaire is both valid and reliable and has been translated into 
French22. The English version of the questionnaire was translated and adapted to 
French and then the French version was back-translated in English by five bilingual 
users. Discrepancies were corrected. The French-Canadian version of the Life-Space 
Assessment (LSA-F) was then validated by 40 French-speaking participants, age 50 
years and over, who had been using a power mobility device for 2-15 months.  
Scores on the two versions were very similar (intra-class correlation coefficient = 
0.87 for LS-C).   
One cross-sectional analysis has shown that visual impairment in older adults 
was associated with reduced life space. This study, for which 909 participants were 
recruited, only measured near visual acuity (at 14 inches using a standard Snellen 
chart), had no information on cause of vision loss, and only examined maximal life 
space, which can be heavily influenced by social support. The relationship between 
specific eye diseases and life space has not been evaluated. 23 
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II.4.b. “Timed Up and Go” Test 
 
The ability to maintain balance both while standing still and while changing 
directions is critical to safe mobility. One measurement commonly used to assess 
dynamic balance is the “timed Up and Go” (TUG) test. It is easy to administer and 
requires only basic mobility skills.  The subject, who can use a mobility aid if 
necessary, is timed in seconds while rising from a chair, walking three meters, 
turning around, walking back and sitting back on the same chair again. The TUG test 
is a simple, inexpensive and broadly used method that was developed to screen basic 
mobility. 
The initial test was developed by Mathias and colleagues24 using a subjective 
5-point rating scale based on the examiner’s perception of the subject’s risk of falls. 
This approach was later revised by Podsialdo and Richardson25 and validated among 
60 elderly patients who were compared with 10 healthy elderly patients admitted to a 
geriatric day hospital. The authors proposed a more objective scoring system. The 
score was equal to the time taken in seconds to complete the test. They found that the 
time was reliable and correlated well with the Berg balance scale, gait speed, and 
limitations in activities of daily living (p < 0.05). 
A study by Shamway-Cook et al26 of 30 adults over age 65 years concluded 
that the TUG test is a valuable tool to identify elderly people who are prone to falls, 
with a sensitivity of 87% and a specificity of 87%. The authors administered the 
TUG under 3 conditions (TUG simple, TUG cognitive - with a subtraction task and 
TUG manual - while carrying a full cup of water).  However, they concluded that the 
ability to predict falls is not increased by adding a secondary task while performing 
the TUG test. Moreover, the TUG plus secondary task scores did not increase the 
ability to identify community-dwelling older adults who are prone to falls.  
One cross-sectional study tried to find the optimal cut-off of the TUG test in 
order to discriminate between community versus long term-care residence dwellers. 
Bischoff et al.27 conducted a study among 491 community-dwelling and 
institutionalized women older than 65 years and they concluded that values below 12 
seconds best explained residency status (this threshold showed discriminative value 
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in the ROC-analysis with an area under the curve of 0.969). Extrapolating to clinical 
practice, they suggested that community-dwelling elders who need more than 12 
seconds to complete the TUG test should receive early evaluation and intervention. 
Moreover, they found out that residential and mobility status were the strongest 
predictors of the timed up and go test (p < 0.001) explaining 54% of the variability in 
TUG times.   
 
 
II.4.c. Balance - One Leg Standing 
 
The one-leg standing test is one of the balance tests most frequently used to 
assess postural steadiness in a static position by quantitative measurement. 28  The 
test is easy to administer; however there are many variations of the one-legged test 
such as opening/closing the eyes, leg selection, number of trials allowed, and number 
of seconds of testing. Performance on this test is associated with many adverse 
outcomes like falls, limitations in activities of daily living, and comorbidities such as 
osteoporosis. 
For example, Vellas et al. conducted a 3-year longitudinal study among 
community-living volunteers older than age 60 years in order to examine if the one-
leg standing test is a predictor for falls and injurious falls. They concluded that the 
inability to maintain balance on one leg for 5 seconds appears to be a significant 
predictor of injurious falls (relative risk = 2.13; 95% CI = 1.04, 4.34; p = 0.03), but 
not to all falls. The authors cautioned that it is difficult to find a unique risk factor for 
falls or fall injuries since there are so many factors involved in falling. 29  
In a prospective study involving 1-year of follow-up conducted in Canada in 
1994, Maki et al. found a relationship between decreased one-leg standing time and 
falls. They administered the balance test to 100 volunteers older than age 62 years 
and measured spontaneous postural sway, induced anterior-posterior sway, induced 
medial-lateral sway, anticipatory adjustments preceding volitional arm movements, 
timed one-leg stance, and performance on a clinical balance assessment scale.  
Lateral stability was found to be the single best predictor of future falling risk. 30 
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Overall, according to Michikawa and colleagues, after reviewing almost 500 
articles which focused on the one-leg standing test and its implications, there is an 
association between the one-leg standing test time and falls, declines in ADL, and 
osteoporosis. In conclusion, this test can be used as a practical tool to screen the 
elderly for falls risk and frailty.31   
 
 
II.4.d. Falls 
 
Falls are a major health care concern for older adults. Studies indicate that 
about one third of older adults living in the community fall every year. 32 
Frequency of falls can be assessed by simply asking the person to recall falls 
over the last 3, 6, or 12 months, by asking people to mail back monthly postcards 
reporting the occurrence of falls, or by asking people to keep a daily diary using a 
customized calendar.  Having people keep a diary is considered the gold standard of 
falls assessment.  Having people retrospectively recall falls will likely lead to an 
underestimate of falls.  A 12 month recall has been shown to be better than a 3 or 6 
month recall. 33  
Older adults who fall are at a greater risk of hospitalization34, nursing home 
admission35, and death36.  A fall can also lead to a fear of falling, which may result in 
decreased mobility37. Research and strategies to prevent falls are necessary.   
 
 
II.4.e. Other Mobility Measures 
 
The Short Physical Performance Battery (SPPB)38 is a composite physical 
performance measure which evaluates gait, balance, and lower extremity strength 
and endurance. The final score of this test is given by summing the scores obtained 
by various tests such as 1) time able to stand with feet together, in the side-by-side, 
semi-tandem, and tandem positions, 2) 2.44 meter walking speed (8-feet), and 3) the 
ability to rise from a chair 5 times without using the arms. Each task is graded from 0 
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to 4, with 0 being the inability to perform the task and 4 being the best performance. 
The composite score of SPPB ranges from 0 (worse performance) to 12 (best 
performance). This SPPB was described for the first time by Guralnik et al.38 In a 
cohort of 5,174 persons aged 71 years and older, they administered the SPPB in the 
home and they evaluated the self-reported physical performance (ADLs, ability to 
walk up and down stairs one floor, and ability to walk a half a mile without help). 
Scores on the three performance tests of SPPB were significantly correlated (p < 
0.01). The authors concluded that the SPPB is useful to distinguish a gradient of risk 
for mortality, nursing-home admission and disability in older people and that 
information provided by self-reported and performance measurements of mobility  is 
complementary, and that both contribute to an understanding of the functional status 
of older adults.  
Another test sometimes used to assess mobility limitations is the ability to 
walk 400 meters (m) at usual pace. Chang et al.39 in a longitudinal study of 21 
months of follow-up found that elderly people with functional limitations have a high 
rate of loss of ability to walk 400m at a usual pace. They enrolled 101 community-
dwelling older adults aged 75 to 85 who were mobile but at greater risk to develop 
future disability (baseline SPPB = 4-9). Only 62 people participated in the follow-up 
(the differences between those lost to follow-up and those who were being followed-
up were not statistically significant). After the follow-up period, 34% of the 
participants developed mobility disability. They found that the time required to walk 
400m at baseline is a significant predictor of mobility loss at follow-up (OR = 1.6 per 
1-minute difference, 95% Cl = 1.04-2.45).   
The disadvantage of the SPPB and the 400m walk is that they take a longer 
time to administer than the other mobility measures I described. In addition, the 
400m walk is difficult to administer in a hospital setting in which space is limited 
and safety is a concern.   
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II.5. Non-visual Risk Factors of Mobility Loss in Old Age 
 
There are a variety of non-visual factors that can increase the risk of mobility 
loss in older age.  Table 1 (page 49) summarizes the most consistent non-visual risk 
factors listing them in the following categories: demographic, comorbid conditions, 
lifestyle, and psychosocial.  
The goal of this study is to determine the ocular causes of mobility loss in 
older adults.  However, this table will be used to determine the factors that may 
confound the relationship between eye disease and mobility loss.   
 
 
II.6. Description of Three Eye Diseases 
 
The focus of this thesis is on:  glaucoma, age-related macular degeneration, 
and Fuchs corneal dystrophy.   
 
 
II.6.1. Glaucoma  
 
Glaucoma is the second leading cause of blindness in the world, according to 
the World Health Organization.40 The term glaucoma includes several types of 
diseases, all being characterized by progressive loss of retinal ganglion cells leading 
to characteristic structural damage to the optic nerve and loss of visual field. Vision 
loss due to glaucoma often first affects peripheral visual field and then can 
progressively also affect central visual field.   
Glaucoma is categorized as open-angle or closed-angle, and each of these 
types can be primary (when the cause is unknown) or secondary (the cause results 
from another disorder). A third type is congenital glaucoma. 
The vision loss due to glaucoma is irreversible. In Canada, in 2002-2003, 
based on a self-report glaucoma study, an estimated 409,000 people were affected 
with glaucoma, with a prevalence of 2.7% in subjects older than 40 years and 11% in 
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people older than 80 years.41 Moreover, this is likely to be an underestimate because 
other research has found that half of people with glaucoma are unaware of their 
disease. 42 
Glaucoma treatment aims to reduce the intraocular pressure. It cannot cure 
the condition, but it can considerably slow or temporarily stop its progress. 
Glaucoma can be treated with medication, laser or conventional surgery.  
Topical glaucoma medication such as eye drops, eye ointments, or inserts are 
the most prescribed. Depending on the mechanism of action, there are many types of 
topical medications (miotics, beta-blockers, prostaglandins analogs, carbonic-
anhydrase inhibitors and alpha-adrenergic agonists), each achieving different 
purposes with the goal of lowering the intraocular pressure. Oral medication can be 
also used for the same purpose. 
The goal of laser treatment is to improve the flow or outflow of aqueous in 
the eye, or to reduce the production of aqueous in order to decrease intraocular 
pressure. There are three types of techniques: trabeculoplasty, iridotomy, or 
cyclophotocoagulation. The goal of surgical treatment is to facilitate the flow of eye 
fluid by either filtration surgery or seton surgery.  
 
 
II.6.2. Age-Related Macular Degeneration  
 
Age-related macular degeneration (AMD) is the leading cause of irreversible 
low vision in developed countries and the leading cause of legal blindness among 
older people in North America. Almost one million Canadians currently have early 
AMD with 250,000 having an advanced form of the disease and 64,000 Canadians 
being blind due to AMD in 2006. The number of people suffering from AMD is 
expected to double by 2031.43 The incidence, prevalence, and progression of all 
forms of AMD increase with advancing age. 44 
The pathological abnormalities in AMD are most pronounced in the central 
part of the retina, in the area centralis, particularly in the central macula, which is 
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responsible for seeing fine details. There are two types of AMD: non-exudative (dry) 
AMD and exudative (wet) AMD.  
Exudative or neovascular AMD is the most damaging type of AMD. It results 
from abnormal proliferation of blood vessels beneath the retina in a process called 
choroidal neovascularization. Although it affects only 10% of those with AMD, this 
type is responsible for 90% of severe vision loss associated with this disorder.45 
Treatment options include laser photocoagulation, photodynamic therapy, or 
injection of intraocular vascular endothelial growth factor (VEGF) inhibitors. 
Generally speaking, non-exudative AMD progresses quite slowly and is 
usually less severe than the exudative type. For non-exudative AMD, treatment 
options include the use of antioxidants and mineral supplements. 46 
 
 
II.6.3. Fuchs Corneal Dystrophy  
 
Fuchs corneal dystrophy (FCD) is a relatively common, bilateral, often 
asymmetric and slowly progressive eye disease in which the inner lining of the 
cornea, the endothelium, changes structure and function and results in swelling, pain 
and loss of vision. It is an inherited autosomal dominant disorder with incomplete 
penetrance that is up to 3 times more frequent in woman. 47 
FCD is a progressive disorder with a typical symptomatic onset in the fifth or 
sixth decade of life with near visual acuity being the most affected at the beginning. 
As an age-related eye disease, FCD will continue to increase in prevalence in our 
aging population. Reliable prevalence estimates of FCD are not available as 
population-based studies have not included FCD.   
 The patient’s vision is usually unaffected during early stages of disease, but 
as the severity increases, patients experience foggy or blurred vision, first only on 
awakening and, then, throughout the day, eye sensitivity to light and to glare, sandy 
or gritty sensation when blinking and, fluctuating vision. In advanced stages, patients 
may experience blurriness or haziness that does not clear throughout the day, severe 
visual impairment and pain from epithelial blisters. 
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Hypertonic saline eye drops or ointments that absorb the excessive fluid out 
of the cornea are used to relieve symptoms of FCD in the beginning. However, the 
only cure for Fuchs’ dystrophy is a corneal transplant (penetrating keratoplasty or 
deep lamellar keratoplasty). Without a corneal transplant, a patient may become 
blind or have severe pain and very impaired vision. Corneal transplant can result in 
substantially improved vision and relief of symptoms with 94% achieving a visual 
acuity of 6/12 or better at three months post-operation. 48 However, transplant 
rejections can occur and corneal tissue availability can be a problem. 49  
 
 
II.7. Measurements of Visual Function Relevant to Mobility 
 
Measures of visual function important to mobility that are affected by eye 
disease including visual acuity, contrast sensitivity, and visual field are described 
below. 
 
 
II.7.1. Visual Acuity 
 
Visual acuity is the most commonly used measure of visual function. It is “a 
measure of the spatial resolving power of the visual system”. 50 Distance visual 
acuity is typically measured by having a person read, from a distance of 2-4 meters, a 
standardized chart of high-contrast letters that gradually decrease in size. Most 
researchers currently use the Early Treatment of Diabetic Retinopathy Study 
(ETDRS) chart to measure visual acuity, which consists of 14 rows with 5 letters per 
row and covers a 20-fold range of letter size. The standard for normal best-corrected 
acuity is 20/20 (in feet), 6/6 (in meters) or 0.0 (in logMAR), although some older 
adults have vision much better than this level. 51 Visual acuity can be measured with 
normal correction (habitual) or with optimal correction (best-corrected) depending on 
the goal.   
 
  
18
 
II.7.2. Contrast Sensitivity 
 
Contrast sensitivity is “the inverse of a measure of the lowest contrast, or 
difference in luminance across borders, an observer can detect”. 50 Diseases like 
cataract, glaucoma, macular degeneration, and multiple sclerosis often limit contrast 
sensitivity. Ideally, contrast sensitivity is measured in a laboratory setting using 
“patches of bars that vary over a wide range of sizes” allowing one to construct a 
contrast sensitivity function. 50 However, for epidemiological research on large 
groups of people, contrast sensitivity is typically measured using the Pelli-Robson 
chart which utilizes a single large letter size in which the letters gradually decrease in 
contrast. This chart reflects contrast sensitivity “near the peak of the contrast 
sensitivity function”. 50 Although contrast sensitivity and visual acuity are 
moderately correlated, contrast sensitivity does provide additional information and is 
often “a better predictor of performance than acuity”. 50  
 
 
II.7.3. Visual Fields 
 
The visual field is the “spatial extent over which the visual system is sensitive 
to light”.50 The visual field can be divided into three regions: macular, central, and 
peripheral region. Many diseases, if severe, can affect the visual field. The visual 
field is typically measured using an automated static perimetry device in which small 
spots of light are shown on a uniform background in all of the locations of the visual 
field. The test does not involve character recognition or resolution, but only the 
detection of light at varying intensities. Visual field testing “is important because it is 
the only clinical test that evaluates vision outside the macula”, or outside the point of 
fixation. 50 Frequency-doubling technology (FDT) was developed in 1997 and allows 
for fast and effective detection of visual field loss. FDT utilises the mechanism 
described by Kelly in 1966, the frequency-doubling illusion, in which a sine wave 
grating of low spatial frequency undergoing counterphase flicker at high temporal 
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frequency appears to the observer to have double the number of bars than are 
actually present. 50  
The FDT perimeter offers two types of test patterns, screening (C-30) and 
threshold tests (C-20 and N-30 which detect what is the minimum contrast that will 
evoke a response from the patient). The C-20 presentation pattern tests the central 
20º with 17 stimulus locations, made up of four 10º-targets per quadrant and a 
circular 5º central one. Two additional points, one presented above and the other 
below the horizontal midline positioned between 20º and 30º in the nasal field, are 
incorporated in the N-30 test. At the end of each eye examination, the fixation point 
is moved temporally in order to test nasal points by redirecting the fixation point 10 º 
temporally. 
FDT provides two global indices to generally summarize the visual field 
results for threshold tests: mean deviation (MD) and pattern standard deviation 
(PSD). MD represents the average sensitivity deviation from a normal healthy person 
of the same age. PSD indicates localized loss, showing how evenly the field loss is 
spread across the visual field. 
The advantages of this technique are that the test is rapid, takes one minute 
for screening and five minutes for the threshold determination, and it is not 
influenced by pupil size.  
The disadvantages are that patients with poor cognitive abilities can have 
difficulty understanding the instructions and it is less capable of discovering early 
scotoma in AMD patients or in discovering visual field loss in certain neuro-
ophthalmologic diseases. 52 
 
 
II.8. Eye Disease and Mobility Loss 
 
II.8.1. Glaucoma and Mobility Loss  
 
There has been little research done examining mobility limitations in patients 
with glaucoma.   
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Turano et al compared the mobility performance of 47 glaucoma patients to 
normal-vision subjects who were of similar age. They evaluated 1) walking speed 
through a predefined course with obstacles to be avoided, 2) if the subjects reported a 
fall or had a fear of falling in the year preceding the evaluation, and 3) vision (visual 
acuity, contrast sensitivity and, monocular and binocular visual fields). They found 
that people with glaucoma had, on average, a reduced walking speed, orientation 
problems and an increased likelihood of bumping into objects, but the differences 
were not statistically significant when compared with people with normal vision. It is 
possible that this study was underpowered with only 47 patients in each group. 53  
In a population-based observational study, Friedman et al. investigated the 
relationship between glaucoma and mobility limitations. They used 1,214 people 
older than 74 years already enrolled in the Salisbury Eye Evaluation Project.  
Mobility was assessed using a predefined course which subjects had to cover as 
quickly and safely as possible while avoiding all obstacles, along with three other 
tests: climbing stairs, walking a straight 4-m course and a 30-second timed stand. 
They measured visual field, visual acuity and contrast sensitivity. After adjustment 
for demographic and health variables, they found that people with bilateral glaucoma 
had decreased mobility performance, walking more slowly and having more bumps 
on the mobility course. Walking speed through the obstacle course was 2.4 
meters/minute slower for those with bilateral glaucoma compared to people without 
glaucoma (p < 0.05). Moreover, people with bilateral glaucoma experienced 1.65 
times the number of bumps when compared with persons without glaucoma (p < 
0.05). 54 How these results translate into real-world mobility difficulties is unknown. 
A study conducted by Shabana et al examining 35 primary open-angle 
glaucoma (POAG) patients and 21 age-matched normal subjects demonstrated that 
individuals with POAG sway more when standing than normal individuals. 
Moreover, the greater sway is associated with more vision damage, indicating the 
existence of a visual contribution to posture at all stages of glaucoma. 55 These 
findings are consistent with those of another study conducted by Black et al in a 
larger sample of POAG patients. Greater sway was associated with increasing VF 
impairment in the better eye. 56  
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One of the consequences of poor balance and/or an increase in bumping into 
things may be more frequent falls. Patients with glaucoma are at an increased risk of 
falls according to two studies. 57, 58 In a cross sectional survey among 3,654 
community-dwelling older adults aged 49 or older in Australia, the frequency of 
falling was associated with posterior subcapsular cataract and use of nonmiotic 
glaucoma medication. Haymes et al. evaluated the frequency of falls (self-reported) 
during the year preceding the evaluation of 48 glaucoma patients when compared 
with 47 controls. After adjusting for age, gender, body mass index, polymedication, 
and better eye Humphrey Field Analyzer (HFA) MD, glaucoma patients had over 3 
times the odds of falling (OR = 3.71; 95%CI = 1.14-12.05) at least once in the 
previous 12 months. 58  This very large odds ratio should be confirmed in further 
research.   
More research is needed on how real-world mobility is impacted in people 
with glaucoma. 
 
 
II.8.2. Age-Related Macular Degeneration and Mobility Loss  
 
Similarly, few studies were found that examined the mobility of people with 
AMD. 
A study by Wood investigated postural stability and gait characteristics of 
older adults with AMD and the visual parameters (binocular high-contrast visual 
acuity, contrast sensitivity, and visual field) associated with postural stability and 
gait. This study included 80 individuals older than 59 years with an AMD diagnosis 
as the unique cause of vision impairment. Postural stability was assessed by asking 
the participant to stay as still as possible for maximum 30 seconds on foam and firm 
surfaces. Information on anterior-posterior and mediolateral sway was assessed 
during this time. Gait was evaluated by measuring stride length, double-support time, 
step width, and walking velocity through a 12-m mobility course at a self-selected 
and comfortable pace. In the separate models, contrast sensitivity, visual acuity, and 
visual field loss were all significantly correlated with postural stability on the foam 
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surface; in the multivariate model only contrast sensitivity was statistically 
associated with postural stability on the foam surface. None of the vision variables 
were correlated with sway on the firm surface. 59 These findings agree with those of 
Waterloo Vision and Mobility study conducted by Spaulding et al. which examined 
specific gait characteristics of AMD-patients and concluded that these patients have 
shorter stride length and longer time for stride and stance. In this study, Spaulding 
recruited 20 AMD patients and 20 age-matched controls. Gait adaptation strategies 
were evaluated with a 6-m path with different texture of surface: compliant, uneven, 
or shiny. 60   
A cross-sectional observational study of 166 adults conducted by Cruess et al. 
evaluated the burden of patients with neovascular AMD when compared with control 
subjects via telephone surveys. The authors used standardized questionnaires to 
assess general health and vision specific quality of life and also asked questions to 
determine the rate of accidents, falls, falls-related injuries, etc. Subjects with AMD 
had more than twice the need for assistance with activities of daily living (p = 0.013) 
and an almost three times higher rate of falls (p = 0.014) when compared with 
controls. 61 However, these results were not adjusted for age and since there was a 
very large difference in age between those with AMD and those without AMD, it is 
likely that these results are confounded.   
Hassan et al. investigated how AMD affects mobility performance and which 
are the vision determinants of mobility among 21 subjects with AMD and 11 age-
matched controls. Mobility was assessed by examining the walking speed on a 20-m 
straight, unobstructed course and then the number and type of obstacles contacted 
during a high-density indoor obstacle course. Vision was assessed through habitual 
visual acuity, contrast sensitivity, and binocular visual field.  There was no difference 
between walking speed and obstacle contact on the mobility course between the two 
groups. 62 However, this study may have been underpowered to detect differences 
with such a small sample size.  
Impaired vision is an important and independent risk factor for falls.63 Studies 
have evaluated the risk of falls among patients with AMD. For example, Szabo et al 
conducted a study in Vancouver among 545 community-dwelling women, between 
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70 and 92 years old, divided into three groups: a group of 115 people with exudative 
AMD  and  two control groups, 54 community-dwelling women without exudative 
AMD drawn from the same community (non-AMD cohort) and 341 community-
dwelling Australian women (Australian normative cohort). They evaluated the risk of 
falls using the short-form Physiological Profile Assessment (PPA), which provides a 
fall risk index score and contains five items: vision, peripheral sensation, lower limb 
strength, reaction time and body sway. The mean fall-risk index score in the AMD 
cohort (3.20) was significantly greater than that of the non-AMD cohort. 64 
 
 
II.8.3. Fuchs Corneal Dystrophy and Mobility Loss  
 
There are no studies that we are aware of that have looked at mobility 
limitations among people with Fuchs corneal dystrophy. 
  
 
CHAPTER III       METHODS 
 
The methods for this project are presented in detail in the manuscript in 
Chapter IV.  Therefore, in this section, pilot data and the sample size calculations 
that were used to plan this study are presented.   
 
 
III.1. Pilot Data 
 
Because life space had rarely been studied in patients with eye disease, we 
collected limited pilot data in the fall of 2008 to determine the variability of the life 
space scores in patients with and without AMD. Over a 3-week period, pilot data 
were collected on life space scores from 16 patients with AMD and 22 similarly-aged 
patients who did not have AMD and who had good vision. Although this is a small 
sample of patients, we found evidence that the AMD group had substantially 
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decreased LS-C scores compared to the group without AMD (average difference = 
8.5, SE = 7.4). We also saw good variability in LS-C scores in our study population 
(range 18-110).   
 
 
III.2. Sample Size Calculation 
 
We performed sample size calculations for the four outcomes of interest in 
order to achieve 80% power to detect associations of the following magnitudes. For 
the LS-C outcome, we required 64 people per group in order to detect a difference in 
LS-C scores of 10 assuming a SD of 20. For the TUG test, we required 64 people per 
group in order to detect a difference in times of 3 seconds between groups assuming 
a SD of 6. For the one-legged balance test, we required 49 people per group to detect 
a 2.6-fold difference in proportions of people with poor balance between groups 
(15% versus 40%). Finally, for falls, we required 58 people per group to detect a 2-
fold difference in proportions of people who fell in the last year (25% versus 50%). 
These calculations all assume a 5% alpha and were made with the PS Power and 
Sample Size Program (Vanderbuilt, TN, USA).  Data used for these calculations are 
based on reasonable assumptions based on our pilot data, other literature, and what 
we believed to be clinically significant differences.   
  
25
 
CHAPTER IV RESULTS 
 
 
 
 
Eye Disease and Mobility Limitations in Older Adults 
 
 
 
 
Mihaela L. Popescu, MD 1, Hélène Boisjoly, MD, MPH 1,2, Heidi Schmaltz, MD 
3, Marie-Jeanne Kergoat, MD 4, Jacqueline Rousseau, PhD 4, Solmaz 
Moghadaszadeh, BSc 1, Fawzia Djafari, MD, MSc 1,2, Ellen E. Freeman, PhD 1,2 
 
 
 
1 Centre de Recherche, Hôpital Maisonneuve-Rosemont, Montréal, Canada; 2 
Département d’ophtalmologie, Université de Montréal, Montréal, Canada; 3 
Department of Geriatric Medicine, University of Calgary, Calgary, Canada;  4 Centre 
de Recherche, Institut universitaire de gériatrie de Montréal, Montréal, Canada 
 
 
Financial Support:   
CNIB New Investigator Grant, Toronto, Canada 
Canadian Institutes of Health Research Grant IAP-98996, Ottawa, Canada 
Fonds de Recherche en Santé du Québec salary award (Dr. Freeman) 
Fonds de recherche en ophtalmologie de l’Université de Montréal salary award 
 (Dr. Popescu) 
 
The funding organizations had no role in the design or conduct of this research. 
No conflicting relationship exists for any author. 
Running Head:  Eye Disease and Mobility Limitations  
Reprint Address:   
Ellen Freeman, PhD 
Hôpital Maisonneuve-Rosemont 
Recherche ophtalmologie, CSA, RC, F131 
5415 boulevard de l’Assomption 
Montréal (QC) H1T 2M4 
CANADA 
 
  
26
ABSTRACT 
Objective:  To examine the extent of mobility limitations in patients with age-related 
macular degeneration (AMD), glaucoma, or Fuchs corneal dystrophy as compared to 
a control group of older adults with good vision.   
Design:  Cross-sectional hospital-based study 
Participants: 253 people (61 with AMD, 45 with Fuchs, 79 with glaucoma, and 68 
controls) 
Methods: Patients were recruited from the ophthalmology clinic of Maisonneuve-
Rosemont Hospital (Montreal, Canada) from September 2009 until October 2010.  
Patients with AMD and Fuchs had to have visual acuity in the better eye of worse 
than 20/40 while patients with glaucoma had to have visual field deficit in their 
worse eye of at least -4dB.  Control patients who had normal visual acuity and visual 
field were recruited from the same clinic.  Questionnaire (life space and falls) and 
performance-based (one-legged balance test, timed Up and Go (TUG) test) mobility 
data were collected, visual acuity, contrast sensitivity, and visual field were assessed, 
and the medical record was reviewed.  Linear and logistic regression were used.   
Main Outcome Measures:  Life space, balance, TUG, falls 
Results:  The three eye diseases were associated with different patterns of mobility 
limitations.  Patients with glaucoma had the most types of mobility limitations as 
they had reduced life space, had worse TUG scores, and were more likely to have 
poor balance than the control group (p < 0.05).  Compared to controls, patients with 
AMD or Fuchs corneal dystrophy had reduced life space (p < 0.05).  Falls were not 
related to eye disease in this study.   
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Conclusions:  The results suggest that eye diseases, especially glaucoma, restrain the 
mobility of older people.  It is important to further explore the impact of eye disease 
on mobility in this population in order to develop interventions that would help 
affected older adults maintain their independence. 
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 INTRODUCTION 
The impact of age-related eye disease on mobility is an important area of 
research given the aging of the population and the importance of mobility in the 
prevention of disability 10 and mortality 11.  Yet, we are only beginning to understand 
the mobility limitations of people with eye disease.  Friedman et al found that people 
with bilateral glaucoma were slower and bumped into more objects on a mobility 
course but the real-world implications of these findings are not known 54.  Some 
small studies have been done on patients with age-related macular degeneration 
(AMD) and have mainly focused on falls and postural stability 59, 61, 62.  We are 
unaware of any studies examining the mobility problems of people with Fuchs 
corneal dystrophy.  More research is needed on how different eye diseases are 
associated with a range of mobility limitations.   
 The first objective was to comprehensively examine several measures of real-
world mobility performance (such as life space, balance, timed Up and Go test 
(TUG), and falls) in people with one of three common age-related conditions (AMD, 
Fuchs corneal dystrophy, and glaucoma) compared to a control group.  These three 
age-related diseases were chosen because they have very different profiles of vision 
loss that might impact mobility in different patterns.  It was hypothesized was that all 
three eye diseases would be associated with the four mobility limitations but that 
diseases with a larger impact on central vision (AMD and Fuchs) would have bigger 
association with restricted life space whereas diseases with a larger impact on 
peripheral vision (glaucoma) would have bigger associations with falls, balance, and 
the TUG test.  The second objective was to determine whether any relationships 
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between eye disease and mobility were primarily explained by visual acuity, contrast 
sensitivity, or visual field.   
 
METHODS 
Study Population   
 All participants were recruited from the ophthalmology clinics at 
Maisonneuve-Rosemont Hospital in Montreal, Canada, between September, 2009, 
and October, 2010.  Three members of the research team (MP, SM, FD) reviewed 
patient files for eligibility each day.  
 All patients had to be 65 or older.  Furthermore, the patients with a clinical 
diagnosis of AMD, Fuchs, or glaucoma had to have at least some vision loss.  
Specifically, the AMD and Fuchs patients had to have disease in both eyes and to 
have best corrected visual acuity worse than 20/40 in their better eye.  Glaucoma 
patients had to have the disease in both eyes and had to have a visual field mean 
deviation worse than or equal to -4dB in their worse eye.  All glaucoma types were 
recruited.  The three groups with eye disease were allowed to have other eye 
diseases.  Finally, the controls had to have best corrected visual acuity of 20/40 or 
better in the better eye and a visual field in the worse eye better than -4dB.  Controls 
either had no current eye disease (63%) or they had non-visually impairing 
conditions such as early cataract (15%), early AMD (4%), ocular hypertension (5%), 
blepharitis (5%), or other (8%).  People who had received eye surgery, laser, or an 
intra-vitreal injection in the last three months were enrolled after a 2-3 month delay 
so that their mobility would not be affected by their recovery.  Patients also had to 
score 10 or better on the Mini-Mental State Exam Blind Version to optimize the 
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reliability of the collection of the self-reported data.  The Blind version of the MMSE 
omits eight items that rely on vision and has been validated against the original 
version 65.  A score of 10 on the Blind version corresponds to a score of 18 on the 
original version, which was used in previous vision research on older adults 66. 
 There were 420 patients who appeared to meet eligibility criteria from a 
review of the medical records.  Of the 420 patients, 300 patients accepted our 
invitation to be in the study (71%), 101 refused (24%), and 19 (5%) were not capable 
of responding for themselves.  Of the 300 who accepted, 253 people met final 
eligibility criteria including 61 with age-related macular degeneration (AMD), 79 
with glaucoma, 45 with Fuchs corneal dystrophy, and 68 people without significant 
eye disease.  Participants were paid $10 for their participation and signed a consent 
form.  The project was approved by the Ethics Committee at the Hospital and the 
research conformed to the tenets of the Declaration of Helsinki.   
 
Data Collection:   
Data were collected in a 1-1.5 hour session by one of three trained research 
personnel.  Participants first answered questions on demographics (age, gender, 
education), mobility, and health.  Then they performed brief mobility, clinical, and 
vision tests. The medical chart was also reviewed.    
 
Mobility   
Questionnaires and performance-based tasks were performed to assess four different 
mobility outcomes.  The Life Space Assessment (LSA) was used to measure the 
spatial extent of participants in a given month 20, 22.  The LSA takes into account the 
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frequency of going to different life space levels (bedroom, driveway, within 
neighborhood, outside neighborhood but within town, out of town) and whether 
assistance was required to get to those levels.  A composite score (LS-C, range 0-
120) is calculated which combines information on the life space level, the degree of 
independence, and the frequency.  The reliability and construct/criterion validity of 
this questionnaire have been published 20.  People were asked if they had fallen in the 
last year, a fall being defined as unintentionally coming to rest on the ground or on 
some other level.  Balance was assessed using the one-legged balance test in which 
the person is asked to stand on the leg of choice with eyes open for up to 30 seconds 
29.  People who cannot stand for 5 seconds on one leg are at an increased risk of 
having an injurious fall 29. Finally, the timed “Up and Go” (TUG) test was performed 
in which a person is asked to rise from a seated position, walk 3 meters, and return to 
the seat while being timed 25.  On previous research studies, the TUG test was found 
to have good reliability and was correlated with gait speed, activities of daily living 
limitations, and balance 25.  Reasons for not doing either the balance test or the TUG 
test were noted (e.g. safety concern of participant or researcher, refusal for non-
safety reasons such as pain).   
 
Health and Anthropometric Measures 
Participants were asked to self-report a physician diagnosis of 13 chronic comorbid 
conditions (e.g. stroke, Parkinson’s, heart disease, diabetes) and whether they were 
currently taking benzodiazepines, a potential falls risk factor 67-69.  A sum of the total 
number of chronic conditions was used to indicate comorbidity, as has been done in 
previous research 54.  Depression was assessed using the Geriatric Depression 15-
  
32
item Scale 70,71.  A score of 5 or greater was used to indicate depression 72.  Cognitive 
status, as mentioned previously, was measured using the Mini-Mental State Exam 
Blind Version which excludes eight items that rely heavily on vision for a total 
maximum score of 22 65.  Height and weight were measured without shoes using a 
Detecto balance scale with height rod (Detecto Medic, Brooklyn, NY).  Body mass 
index was calculated as kg/m2.  Obesity was defined as a body mass index of 30 
kg/m2 or greater.   
 
Vision and Eye Disease 
Binocular habitual visual acuity was measured using the ETDRS chart with 
illuminated light box at 2 meters or at 1 meter if the participant could not read any 
letters at 2 meters 73, 74.  Letter by letter scoring was performed with scores at 2 
meters converted to scores at 1 meter by adding 15. Contrast sensitivity was 
measured using the Pelli-Robson chart at 1 meter for each eye 75.  Visual field was 
measured using the Humphrey FDT test for each eye 76.  The medical record was 
reviewed and information on severity of eye disease and coexisting eye disease was 
recorded.  Those who could not perform the FDT test because of advanced eye 
disease had their last visual field exam results taken from the medical record.   
 
Outcomes 
The LS-C and TUG scores were examined as continuous variables given the 
approximately normal distribution of their scores.  The other outcomes were 
dichotomized.  The balance time was dichotomized at 5 seconds due to the truncated 
nature of the measurement at 30 seconds and due to the previous finding that a time 
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of 5 seconds or less was indicative of a recent fall 29.  Falls were examined as having 
reported a fall in the last year or not.   
 
Statistical Analyses  
Descriptive statistics were calculated including means, standard deviations, and 
percentages.  Vision, demographic, health, and mobility variables were compared for 
the three eye disease groups and the control group using ANOVA or chi-square tests.  
Next, to determine if eye disease was independently associated with any of the 
mobility outcomes, regression was used to adjust for potential confounding.  The 
different disease groups (AMD, glaucoma, and Fuchs dystrophy) were entered as 
indicator variables in the regression model with the control group as the reference.  
Linear regression was used to determine if LS-C or TUG scores differed for any of 
the eye disease groups compared to the control group after adjustment for 
demographic and health variables including age, gender, education, body mass index, 
depression, number of comorbidities, benzodiazepine use, and cognitive status.  Race 
was not included in the regression models due to the absence of non-white patients in 
certain eye disease groups.  The relationship between eye disease and the 
dichotomous outcomes (falls, balance) were examined using logistic regression.  
 
To determine the measures of visual function primarily explaining the relationships 
between eye disease and mobility, the five measures of visual function (binocular 
visual acuity, contrast sensitivity in the better or worse eye, visual field in the better 
or worse eye) were entered one at a time into the model with the eye disease variable, 
and the visual function variable causing the maximal change in the regression 
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coefficients for the eye disease variables was noted.  Analyses were done in Stata 
Version 11.0 (College Station, Texas).   
  
RESULTS 
 Two hundred fifty-three patients who resided in the community (81%), in 
assisted living (10%) or in a retirement home (9%) were recruited into the study.  In 
Table 1, the demographic, visual, and health characteristics of the four groups are 
compared.  The groups with eye disease were older than the control group (p < 
0.001).  The AMD and Fuchs groups had a higher percentage of women than the 
glaucoma or control groups (p = 0.001).  The glaucoma group had a greater 
percentage of patients of African descent than the other groups, which had none to 
one patient of African descent.  The groups with eye disease had worse cognitive, 
depression, and comorbidity scores (p < 0.001) while there was no significant 
difference in obesity between the groups.   
 As expected, visual acuity and contrast sensitivity were worst in the AMD 
and Fuchs groups while visual field was worst in the glaucoma group (p < 0.001) 
(Table 1).  The binocular visual acuity in the AMD group was 0.73 logMAR (~20/90 
Snellen), in the Fuchs group was 0.64 logMAR (~20/80 Snellen), in the glaucoma 
group was 0.33 logMAR (~20/45 Snellen), and in the control group was 0.04 
logMAR (~20/20 Snellen).  The glaucoma patients mainly had primary open-angle 
glaucoma (79%), 8% had normal tension glaucoma, 5% had secondary glaucoma, 
while the rest had other forms or the medical record did not specify (8%). The mean 
pachymetry value in the worse eye of the Fuchs patients was 691 μm (SD = 109).   
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 In unadjusted analyses, the three groups with eye disease had worse average 
life space and TUG times and were more likely to have poor balance, not to drive, 
and to do no regular exercise (p < 0.05) (Table 2).  There were no differences among 
the groups for having fallen in the last year (p = 0.265).  The presence of injurious 
falls and the number of falls in the last year also did not significantly differ among 
the groups (data not shown).   
 In linear or logistic regression models adjusting for demographic and health 
variables, all three groups with eye disease had worse life space.  Patients with AMD 
had life space scores that were 15 points lower on average (95% CI = -23, -6) than 
the control patients while patients with Fuchs and glaucoma had life space scores that 
were 12 (95% CI = -20, -3) and 11 points (95% CI = -18,-4) lower respectively 
(Table 3).   
 Patients with glaucoma had worse scores on the TUG test and the one-legged 
balance test (Tables 3-4 respectively).  Glaucoma patients took 1.6 seconds longer (p 
= 0.026) on average to complete the TUG test and had 4.1 times the odds (p = 0.005) 
of being unable to hold balance for 5 seconds compared to control patients.  Patients 
with AMD or Fuchs did not perform significantly worse on these tests compared to 
controls.  
 None of the eye disease groups were more or less likely to fall (Table 4).  
Secondary analyses examining two or more falls or fall number also did not indicate 
associations (data not shown).  
 In order to determine which of the three measures of visual function 
explained the biggest part of the relationship between each eye disease and each 
mobility outcome, each measure of visual function was entered separately into the 
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regression models while keeping the number of observations constant between the 
models with and without the measure of visual function (data not shown).  For life 
space, contrast sensitivity in the worse eye explained the biggest parts of the 
relationships for AMD, Fuchs, and glaucoma.   For the TUG score, visual field in the 
better eye explained the biggest part of the relationship with glaucoma.  For the 
balance test, contrast sensitivity in the better eye explained the biggest part of the 
relationship with glaucoma.   
 
DISCUSSION 
 All patients with vision loss had reduced mobility, but the pattern of mobility 
impairment differed by diagnosis.  The results indicate that patients with glaucoma 
had the highest number of mobility limitations with reduced life space, slower TUG 
times, and poorer balance.  Patients with AMD had the most reduced life space.  The 
measures of visual function that explained these relationships differed depending on 
the mobility task.  For example, the relationship between glaucoma and balance was 
explained mainly by contrast sensitivity while the relationship between glaucoma 
and the TUG time was explained mainly by visual field.   
 The hypothesis was partially confirmed in that AMD had the largest 
association with life space, but glaucoma also showed strong associations with life 
space.  Glaucoma was related to the TUG time and to poor balance, but it was not 
related to falls.  It was expected that diseases affecting peripheral vision would have 
a bigger impact on balance and falls due to prior research showing the importance of 
visual field on postural stability, falls, and balance56, 77, 78 .  Additionally, it was 
anticipated that the Fuchs patients would be more similar to the AMD patients.  
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While Fuchs can affect both central and peripheral vision, the Fuchs participants had 
decreased visual acuity and contrast sensitivity but only modestly decreased visual 
field.  The Fuchs participants in the study had reduced life space, similar to the AMD 
participants, as expected.   
 This study is novel in its ability to examine a range of mobility outcomes 
across patients with different eye diseases compared to controls without significant 
vision loss.  Validated measures of mobility that have been found to be associated 
with a range of adverse health outcomes were utilized 20, 25, 29.  To our knowledge, no 
previous studies have examined the relationships between the eye diseases of interest 
and life space, TUG time, or the one-legged balance test.  Previous research has been 
done examining postural sway in glaucoma patients or AMD patients 55, 56, 59.  The 
present results for one-legged balance support these studies.   
 The lack of associations between the eye diseases and falls was surprising, 
given that various measures of visual function have been associated with falls in 
other research 4, 57, 63, 78-80.  Few studies have examined falls in a population of 
patients with eye disease.  One study found that glaucoma patients had over three 
times the odds of a self-reported fall compared to controls (OR = 3.71, 95%CI = 
1.14, 12.05) 58.  This study did not replicate this finding, possibly due to differences 
in the control selection.  Controls in the previous study were recruited by public 
notices within a Health Sciences Centre, while controls in this study were patients 
without significant vision loss from the same ophthalmology clinic in order to be as 
similar as possible to the cases.  In a study of AMD and falls, one study found that 
neovascular AMD patients were three times more likely to fall than people without 
AMD (p = 0.014) 61.  However, adjusted results for falls were not given and it is 
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possible that these results are affected by confounding, given the 17-year age 
difference between those with and without AMD.   Despite the lack of an association 
with falls in the present data, glaucoma was associated with worse TUG times and 
poor balance, two mobility outcomes that are themselves related to falls or disability 
25, 29.  It is possible that patients with eye disease have developed compensatory 
strategies (such as reduced life space) or gait adaptations to avoid falling 60.  Another 
possibility is significant misclassification of the self-report of falls. 
 Not surprisingly, other known risk factors for mobility limitations affected the 
outcomes of the study participants with eye disease.  People whose GDS-15 scores 
suggested depression had worse mobility outcomes.  For example, they had lower 
life space scores, were more likely to have poor balance, and were more likely to 
have fallen compared to people without depression (p < 0.05).  A large percentage 
(25%) of the study population met the criteria for depression using a cutoff of 5 or 
greater.  It appears that there was a great unmet need for depression treatment in the 
study population.  It was suggested to people whose scores indicated depression that 
study should consider consulting with their primary care physician about treatment 
options.  Also, women had more mobility limitations than men as they had lower life 
space scores, slower TUG times, and were somewhat more likely to have poor 
balance (p = 0.086) (Tables 3-4).  The present data fit with prior research indicating 
that women have a greater incidence of mobility disability than men 81.  This study 
was not designed to examine interaction between eye disease and other factors such 
as depression or gender, but future research should examine whether there is a 
synergistic effect on mobility limitations.    
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 Strengths of this study include the inclusion of multiple questionnaire and 
performance-based measures of mobility, the examination and comparison of people 
with different eye diseases representing different patterns of vision loss, the 
measurement of visual acuity, contrast sensitivity, and visual field, and the inclusion 
of many potential confounding factors in the analysis.   
 A limitation of this study is the use of self-reported data to measure the falls.  
The validity of the retrospective falling question was found by Cumming et al to 
have a correlation of 0.6 with the prospective reporting of falls with a 12-month 
recall being better than a shorter recall of 3 or 6 months 33.  Also, participants in this 
study come from a single hospital rather than a population-based study making the 
possibility of selection bias more likely.  However, all of the patients with and 
without eye disease came from the same department of the hospital, 94% of patients 
live within a 1-hour drive, and the response rate of our patients was high at 71%.  
Finally, the Fuchs group was smaller than the other groups (n = 45) resulting in more 
limited power for that group.  However, generally, there was good power to detect 
reasonably sized relationships with all mobility outcomes as the many statistically 
significant findings demonstrate.  
 Different eye diseases were found to be associated with different patterns of 
mobility limitations.  This knowledge is relevant to those providing low vision 
rehabilitation services and to patients with moderate to severe eye disease and their 
families.  Despite the great advancements being made in the treatment of age-related 
eye disease, millions of people are still faced with the stark reality that their 
deteriorating vision makes it difficult to maintain the active lifestyle they once had.  
Keeping older adults with eye disease as mobile as possible may help prevent 
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morbidity associated with a sedentary lifestyle, mobility disability and ultimately 
mortality in this vulnerable population. 
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Table 1:   Description of four study groups 
 AMD 
Mean 
(SD) or % 
n=61 
Fuchs 
Mean 
(SD) or % 
n=45 
Glaucoma 
Mean (SD) 
or % 
n=79 
Controls 
Mean (SD) 
or % 
n=68 
 
P-value 
Age 82.8 (5.4) 79.1 (7.0) 76.7 (7.5) 72.8 (4.7) 
 
<0.001 
Female gender 79% 84% 57% 65% 
 
0.001 
Caucasian  
African descent 
100% 
0% 
100% 
0% 
87% 
13% 
99% 
1% 
 
<0.001 
Obese 
 
17% 20% 22% 15% 0.729 
Binocular visual 
acuity, letters 
correct 
 
48.7 
(19.4) 
 
53.0 (15.0) 
 
68.4 (16.0) 
 
82.8 (3.2) <0.001 
Binocular visual 
acuity, logMAR 
 
0.73 
(0.39) 
0.64 (0.30) 0.33 (0.32) 0.04 (0.06) <0.001 
Contrast 
sensitivity in better 
eye, letters correct 
 
24.8 (7.9) 25.7 (7.0) 28.9 (7.6) 39.2 (2.8) <0.001 
Visual field in 
better eye, MD 
 
-3.2 (3.9) -3.0  (3.9) -9.6 (6.7) 0.5 (2.1) <0.001 
Mini-Mental Blind 
Version (max 22) 
 
18.9 (2.8) 19.6 (2.5) 19.1 (2.9) 20.8 (1.4) <0.001 
Depressive 
symptoms 
 
3.6  (2.9) 3.3 (2.7) 
 
2.6 (2.5) 
 
1.3 (1.8) 
 
<0.001 
Comorbidity Score 3.3 (2.0) 
 
2.7 (1.7) 
 
2.6 (1.6) 
 
2.0 (1.5) 
 
<0.001 
Benzodiazepine 
Use 
36% 35% 18% 15% 0.009 
 
 
AMD=age-related macular degeneration 
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Table 2:   Unadjusted mobility scores of four groups 
 
 AMD 
Mean (SD) 
or % 
n=61 
Fuchs 
Mean (SD) 
or % 
n=45 
Glaucoma 
Mean (SD) 
or % 
n=79 
Controls 
Mean (SD) 
or % 
n=68 
 
P-Value‡ 
Life Space 
 
37.61(17.73) 47.14(24.44) 54.28(25.72) 72.21(18.88) <0.001 
Poor Balance*  
 
65% 43% 54% 22% <0.001 
TUG time† 
 
13.6 (4.9) 13.3 (5.7) 12.8 (6.0) 9.6 (2.2) <0.001 
Fallen in last year 30% 
 
27% 
 
37% 
 
22% 
 
0.265 
 
AMD=age-related macular degeneration; TUG=timed Up and Go 
 
*includes the 204 people who agreed to perform the balance test.  48 people did not 
participate due to safety concerns, use of wheelchair or walker, or non-safety 
concerns such as pain.  For 1 person, the reason for non-participation is missing.  
 
†includes the 233 people who performed the TUG. 20 people did not participate due 
to safety concerns or refusal.  
 
‡ p-value is from ANOVA (continuous variables) or chi-square tests (categorical 
variables) 
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Table 3:  Linear regression results on adjusted relationship between eye disease 
and continuous mobility outcomes.  
 
 Life Space 
   β               P-value 
TUG Time 
 β               P-value 
Control 
AMD 
Fuchs Dystrophy 
Glaucoma 
 
  0.00 
-14.66           0.001 
-11.66           0.006 
-10.78           0.002 
 0.00 
-0.20           0.832 
 1.41           0.123 
 1.64           0.026 
Age 
 
-0.85           <0.001  0.25         <0.001 
Female Gender 
 
-11.07         <0.001  1.73           0.006 
Education 
 
 0.51              0.157 -0.04           0.565 
Obese 
 
-2.08              0.549  1.89           0.014 
MMSE Blind Version 
 
 0.81              0.164 -0.17           0.215 
Depression 
 
-12.94          <0.001 0.59            0.398 
Comorbidity Score -2.08              0.019 0.28            0.152 
 
Benzodiazepine Use 
 
 2.34              0.486 -0.09           0.898 
 
CI=confidence interval; AMD=age-related macular degeneration; TUG=timed Up 
and Go 
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Table 4:  Logistic regression results on adjusted relationship between eye 
disease and dichotomous mobility outcomes.  
 
 Poor  
Balance 
OR      P-value 
Fallen in Last Year 
OR       P-value 
Control 
AMD 
Fuchs 
Glaucoma 
 
1.00 
1.23      0.742 
1.45      0.561 
4.10      0.005 
1.00 
1.07      0.901 
1.09      0.877    
1.79      0.172 
Age 
 
1.22    <0.001 1.00      0.961 
Female Gender 
 
2.10      0.086 1.27      0.514 
Education 
 
0.91      0.073 0.94      0.187 
Obese 
 
0.70      0.489 0.75      0.509 
MMSE Blind 
Version 
 
1.16      0.081 1.05      0.520 
Depression 
 
4.02      0.004 2.30      0.021 
Comorbidity Score 
 
1.12      0.385 0.97      0.775 
  
Benzodiazepine 
Use 
0.69      0.461 0.96      0.923     
 
OR=odds ratio; CI=confidence interval; AMD=age-related macular degeneration; 
BMI= body mass index;  
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CHAPTER V                     DISCUSSION 
 
 
The general objective of this Master’s thesis was to determine if older 
patients with eye diseases are more likely to have mobility limitations. The 
hypothesis tested was that patients with eye disease such as age-related macular 
degeneration, glaucoma, or Fuchs corneal dystrophy would have reduced mobility 
and that their mobility would be limited in different ways depending on the type of 
eye disease. Several points related to the results have been discussed in the 
manuscript in Chapter IV. This discussion will elaborate more on the results and is 
divided into three sections. The first section summarizes the findings on the 
association between eye disease and mobility. The second section presents the 
strengths and limitations of the study in more detail. Finally, the third section 
addresses the clinical implications of the results and the need to conduct future 
longitudinal research on this topic in order to be able to examine the temporal 
relationship between the onset of eye disease and the loss of mobility. 
 
 
V.1. Eye Disease and Mobility Loss 
 
This study provides evidence that patients with eye diseases such as age-
related macular degeneration, glaucoma, or Fuchs corneal dystrophy all had mobility 
restrictions. However, in terms of the types of mobility that were impaired – life 
space, timed Up and Go (TUG) test, balance, or falls – the groups were affected 
differently.  
Life space scores were lowest in the patients with AMD as they were 15 
points lower than control patients, on average. However, there was a range of life 
space scores among AMD patients as the scores ranged from a low of 9 to a high of 
92. The strong relationship between AMD and life space is primarily explained by 
the driving status of the patient. When driving status is entered into the regression 
model, the association between AMD and life space is cut in half but it is still 
statistically significant.  Glaucoma and Fuchs patients also had reduced life space 
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scores that were 12 and 11 points lower than those of controls. The value of the life 
space questionnaire is that it gives a summary of how mobile a person is in the 
community and it combines information on driving, social support, walking ability, 
and balance. Clearly, patients with the eye diseases in this study are not as mobile as 
control patients with good vision.   
In contrast, patients with glaucoma suffered from decrements in both dynamic 
and static balance while patients with AMD and Fuchs did not. It is known from 
other literature that visual field is important to postural sway and balance. Other 
measures of visual function that were not examined in the present study may also be 
important to balance, such as motion detection threshold, which is the ability to 
detect small movements.82 For a test that took control patients 10 seconds on average 
to perform, it took the glaucoma patients 16% longer. If one imagines all the 
dynamic balance tasks that one performs over the course of a day, this could translate 
into substantially decreased function. Similarly, glaucoma patients had 4.1 times the 
odds of having poor balance, which was defined as being unable to hold the one-
legged stand for 5 seconds. Patients with glaucoma may not realize that they are at 
risk for difficulties with balance, especially if their central vision is still good.   
Surprisingly, no associations were found between eye disease and falls during 
the year preceding the interview. No associations were found when examining 
injurious falls or fall number. This was unexpected and could be due to the 
measurement of falls, which was based on self-report, or due to compensatory 
strategies used by patients with eye disease that may lower the risk of falls. Older 
adults routinely use compensatory strategies when faced with decreased functional 
abilities. For example, they may reduce their life space; they may restrict their 
driving; they may use a mobility aid; or they may change their gait.  All these 
compensatory strategies could affect the risk of having a fall.  This study was not 
focused on compensatory strategies, but further research could examine the use of 
compensatory strategies in patients with eye disease.   
One goal of the present study was to determine which measure of visual 
function (VA, CS, or VF) best explains the relationship between eye disease and 
mobility limitations. Interestingly, contrast sensitivity was the measure of visual 
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function that most explained the relationships between all three eye diseases and life 
space. Contrast sensitivity has been previously found to be important for car 
crashes83 and falls63, but many studies do not include a measure of contrast 
sensitivity, preferring instead to only measure visual acuity.  Visual field impairment 
best explained the relationship between worse TUG score and balance in glaucoma 
patients. This concurs with what is known about the importance of visual field and 
postural stability. 56  
The other factors that were important in this study included depression, 
obesity, comorbidity, and gender. Screening for depression using the GDS-15, it was 
found that one-quarter of the cohort met the criteria for depression. Patients with 
depressive symptoms had lower life space, worse balance, and were more likely to 
have fallen. Patients who were obese had a longer TUG time. Patients with more 
comorbidity had more restricted life space.  Women had reduced life space and 
longer TUG times.   
 
 
V.2. Strengths and Limits of the Study 
 
 This study was novel in its recruitment of patients with three different eye 
diseases compared to a control group with good vision in order to compare a wide 
variety of both questionnaire and performance-based mobility measures. No studies 
have been done to examine the mobility of patients with Fuchs corneal dystrophy. 
Mobility was assessed using standardized and validated instruments. The mobility 
chosen measures are important for independent living. Data on potential confounders 
such as age, gender, chronic health conditions, body mass index, depression, 
educational attainment, cognitive status, and benzodiazepine use were also collected. 
All potential patients were approached and response rate was recorded. There was a 
representative sample of eligible patients from the clinic. There was a 71% response 
rate in this study.   
There are some limitations of the study.  Because it was cross-sectional, one 
cannot make any assumptions regarding the temporality of the onset of eye disease 
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and the onset of mobility loss. A longitudinal design would have offered more 
insight in ascertaining the temporal order of circumstances surrounding the mobility 
loss and would allow examination of the trajectory of mobility loss over time. One 
concern about the inability to show temporality is the risk of reverse causality. It was 
hypothesized that patients with eye disease must reduce their mobility because of 
their vision. However, it is also possible that patients who develop mobility 
limitations due to other factors then go on to develop more severe eye disease due to 
an inability to properly care for the eyes.  For example, a patient confined to a wheel 
chair without adequate social support may develop more severe glaucoma because he 
cannot get to the clinic to be examined and to be given proper treatment. This is why 
longitudinal data are needed to properly establish temporal relationships.    
Another limitation is the generalizability of the findings beyond the 
population who match the characteristics of those patients in this study. These 
patients all had bilateral eye disease of a certain severity and had fairly good 
cognitive scores to allow them to answer the questionnaires. The patients all attended 
one tertiary care clinic in Montreal and were predominantly of Caucasian ethnicity. 
Whether the findings generalize to other ethnic groups and hospitals is not known.   
Another limitation is usage of self-reported data regarding life-space and 
falls. The advantage of self-reported data is that it is easy to obtain, compared to 
asking patients to keep a diary or obtaining health records for an injurious fall. 
However, the disadvantage is that self-reported data can be misclassified due to 
problems with memory or lack of honesty. Recall bias may explain why falls during 
the year preceding the interview were not related with mobility limitations, since 
falls tend to be forgotten if they are non-injurious. 33 Also, under-reporting of falls 
might have occurred because of a reluctance to admit falling, because of fear that 
recognizing it could be a sign of aging. Recall bias can result in nondifferential 
misclassification which can bias results to the null, which could explain the negative 
findings for falls.   
Finally, another limitation was the relatively small size (n=45) of the Fuchs 
corneal dystrophy group. There was only 58% power to detect the relationship 
between Fuchs and an increased average TUG time of 1.4 seconds with 45 patients.  
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If the target number of 80 patients had been recruited, there would have had 71% 
power to detect this association or 82% power to detect an increased TUG time of 
1.6 seconds.  However, despite the smaller size of the Fuchs group, there was still a 
statistically significant association between Fuchs and life space.   
  
 
V.3. Clinical Implications and Future Research 
 
 This study is the first step in identifying the mobility limitations of patients 
with eye disease. It makes an important contribution to the knowledge of patients, 
their families, and their physicians. Patients with eye disease may benefit from 
knowledge that their balance may be affected. They may use this knowledge to take 
steps to protect themselves. Families of patients may also find this information 
beneficial.  They may take steps to make the living environment of the patient with 
eye disease more secure and may try to be more available for accompanying patients 
with eye disease on trips.  Finally, low vision rehabilitation providers may find this 
study useful in order to better help patients with eye disease deal with mobility 
limitations like impaired balance or reduced life space. Moreover, older adults with 
eye disease may benefit from a comprehensive geriatric evaluation and the 
elaboration of a treatment plan to address modifiable non-visual risk factors for 
mobility problems like benzodiazepine use.  
 This study provides a scientific rationale for future longitudinal investigations 
to examine the trajectory of mobility loss over time and to learn whether mobility 
limitations such the ones studied are preventable in patients with eye disease.  
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Table 1: Non-visual risk factors for mobility limitations 
 
 
Category 
of risk factors 
Subsystems 
 
Demographic 
Age - older age2, 84 
Gender - female gender81 
Marital status - single marital status2 
Social economic status - low income, less than 25.000 per year 
(inaccessibility to transportation, fitness classes, mobility aid 
devices)2 
Educational level - less than high school education2 
 
 
 
 
Comorbidities 
Cognitive status85, 86 
Muscles mass, power and strength87  
Bone and joints integrity88 
Cardio-vascular disease88, 89 
Respiratory function88 
Acute illness88 
Lifestyle factors Smoking90 
Obesity (BMI>30) 91, 92 
Sedentary lifestyle86 
Driving93 
 
Psychosocial 
 
Depression94 
Falls and fear of falling30, 95 
Interpersonal dependency96 
Social relationships97 
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FIGURE 1.a.  Life Space Assessment - English version 20 
 
Name: Date: 
These questions refer to your activity just within the past month. 
LIFE-SPACE LEVEL FREQUENCY INDEPENDENCE SCORE 
During the past four weeks, have you 
been to … 
How often did you get there? Did you use aids or 
equipment? 
Did you need help 
from another person? 
Level 
X 
Frequency 
X 
Independence 
Life-space level 1 … 
Other rooms of your 
home besides the room 
where you sleep? 
Yes 
 
 
 
 
 
1 
No 
 
 
 
 
 
0 
Less 
than 1 
/week 
 
 
 
1 
1-3 
times 
/week 
 
 
 
2 
4-6 
times 
/week 
 
 
 
3 
Daily 
 
 
 
 
 
4 
1=Personal assistance 
1.5=Equipment only 
2=No equipment or 
personal assistance 
 
 
 
 
 
Score                           X                                                            X                  = Level 1 Score 
Life-space level 2 … 
An area outside your 
home such as your porch, 
deck or patio, hallway (of 
an apartment building) or 
garage, in your own yard 
or driveway? 
Yes 
 
 
 
 
 
2 
No 
 
 
 
 
 
0 
Less 
than 1 
/week 
 
 
 
1 
1-3 
times 
/week 
 
 
 
2 
4-6 
times 
/week 
 
 
 
3 
Daily 
 
 
 
 
 
4 
1=Personal assistance 
1.5=Equipment only 
2=No equipment or 
personal assistance 
 
 
 
 
 
Score                           X                                                            X                  = Level 2 Score 
Life-space level 3 … 
Places in your 
neighbourhood, other than 
your own yard or 
apartment building? 
Yes 
 
 
 
 
3 
No 
 
 
 
 
0 
Less 
than 1 
/week 
 
 
1 
1-3 
times 
/week 
 
 
2 
4-6 
times 
/week 
 
 
3 
Daily 
 
 
 
 
4 
1=Personal assistance 
1.5=Equipment only 
2=No equipment or 
personal assistance 
 
 
 
 
 
Score                           X                                                            X                  = Level 3 Score 
Life-space level 4 … 
Places outside your 
neighbourhood, but 
within your town? 
Yes 
 
 
 
 
4 
No 
 
 
 
 
0 
Less 
than 1 
/week 
 
 
1 
1-3 
times 
/week 
 
 
2 
4-6 
times 
/week 
 
 
3 
Daily 
 
 
 
 
4 
1=Personal assistance 
1.5=Equipment only 
2=No equipment or 
personal assistance 
 
 
 
 
 
Score                           X                                                            X                  = Level 4 Score 
Life-space level 5 … 
Places outside your town? 
Yes 
 
 
 
 
5 
No 
 
 
 
 
0 
Less 
than 1 
/week 
 
 
1 
1-3 
times 
/week 
 
 
2 
4-6 
times 
/week 
 
 
3 
Daily 
 
 
 
 
4 
1=Personal assistance 
1.5=Equipment only 
2=No equipment or 
personal assistance 
 
 
 
 
 
Score                           X                                                            X                  = Level 5 Score 
                                                                                                                         TOTAL SCORE (ADD) 
                                                                                                                                  
Sum of levels 
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FIGURE 1.b.  Life Space Assessment - French version 22 
 
LES QUESTIONS SUIVANTES 
CONCERNENT SEULEMENT 
VOS ACTIVITÉS DU DERNIER 
MOIS. AU COURS DES 
QUATRE DERNIÈRES 
SEMAINES, ÊTES-VOUS ALLÉ 
…  
A. AU COURS DES 
QUATRE DERNIÈRES 
SEMAINES, COMBIEN DE 
FOIS ÊTESVOUS ALLÉ…?  
COMMENT VOUS Y ÊTES VOUS RENDU?  
B. Avez-vous utilisé des 
aides techniques ou un 
équipement particulier pour 
vous rendre …?  
C. Avez-vous eu besoin 
de l’aide d’une personne 
pour vous rendre …?  
  
Oui 
 
Non  Moins 
de 1 
fois par 
sem.  
 
1 à 
3 
fois 
par 
sem 
 
4 à 
6 
fois 
par 
sem 
 
Tous 
les 
jours  
 
Oui  
 
Non  Ne sait 
pas OU 
préfère ne 
pas 
répondre  
 
Oui 
 
Non  Ne sait 
pas OU 
préfère ne 
pas 
répondre  
DANS DES 
PIÈCES DE 
VOTRE 
DOMICILE, 
AUTRES QUE 
CELLE OÙ VOUS 
DORMEZ? AIRE 
DE MOBILITÉ 1 
Ο       Ο 
 
 (LS1)  
    Ο           Ο         Ο            Ο  
 
(LS1F)  
     Ο         Ο             Ο  
 
(LS1A)  
   Ο       Ο           Ο  
 
(LS1H)  
AUTOUR DE 
VOTRE 
DOMICILE, 
comme sur votre 
galerie, votre 
balcon, votre 
terrasse, dans les 
couloirs (immeuble 
d’habitation), dans 
le garage, sur votre 
terrain ou dans 
votre entrée de 
cour?  AIRE DE 
MOBILITÉ 2  
Ο       Ο  
 
(LS2)  
    Ο          Ο         Ο           Ο  
 
(LS2F)  
       Ο        Ο            Ο  
 
(LS2A)  
    Ο        Ο         Ο  
 
(LS2H)  
DANS VOTRE 
VOISINAGE,  Ο       Ο     Ο            Ο          Ο            Ο        Ο         Ο            Ο      Ο         Ο          Ο  
au-delà de votre 
cour ou de votre 
    
 immeuble      
d’habitation? AIRE 
DE MOBILITÉ 3  (LS3)  (LS3F)  (LS3A)  (LS3H)  
DANS VOTRE 
VILLE, au-delà de 
votre voisinage? 
AIRE DE 
MOBILITÉ 4  
Ο       Ο 
(LS4)  
  Ο              Ο          Ο           Ο 
(LS4F)  
     Ο           Ο           Ο  
(LS4A)  
    Ο        Ο          Ο  
(LS4H)  
À L’EXTÉRIEUR 
DE VOTRE 
VILLE? AIRE DE 
MOBILITÉ 5  
Ο       Ο 
(LS5)  
  Ο              Ο           Ο          Ο 
(LS5F)  
    Ο            Ο           Ο  
(LS5A)  
     Ο        Ο           Ο  
(LS5H)  
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